Table 3.
(a) Univariate analysis. (b) Multivariate analysis
| (a) Univariate analysis | |||||||
|---|---|---|---|---|---|---|---|
| N = 204 (%) | Overall survival | Relapse free survival | |||||
| HR | CI |
p Value (log rank) |
HR | CI |
p Value (log rank) |
||
| Age | |||||||
| Pediatric | 140 (68.6) | 1.000 | < 0.001 | 1.000 | < 0.001 | ||
| Adult | 64 (31.4) | 3.626 | 2.03–6.45 | 3.608 | 1.79−7.26 | ||
| Cell phenotype | |||||||
| B-cell | 130 (63.7) | 1.000 | 0.27 | 1.000 | 0.09 | ||
| T-cell | 74 (36.3) | 1.366 | 0.77–2.40 | 1.773 | 0.90−3.48 | ||
| Sex | |||||||
| Female | 70 (34.3) | 1.000 | 0.39 | 1.000 | 0.21 | ||
| Male | 134 (65.7) | 0.78 | 0.44–1.38 | 0.648 | 0.32−1.29 | ||
| Hyperleucocytosis | |||||||
| Absent | 122 (59.8) | 1.000 | 0.89 | 1.000 | 0.60 | ||
| Present | 82 (40.2) | 0.896 | 0.53–1.72 | 0.826 | 0.4−1.70 | ||
| Risk type | |||||||
| Standard risk | 65 (32) | 1.000 | 0.14 | 1.000 | 0.15 | ||
| High risk | 139 (68) | 1.61 | 0.85–3.04 | 1.78 | 0.8−3.95 | ||
| Remission | |||||||
| Yes | 179 (87.7) | 1.000 | < 0.001 | 1.000 | 0.13 | ||
| No | 25 (12.3) | 4.86 | 2.67–8.84 | 2.09 | 0.8−5.43 | ||
| Cytogenetics | |||||||
| Normal cytogenetics | 81 (39.7) | 1.000 | 1.000 | ||||
| Favourable | 36 (17.6) | 0.363 | 0.12–1.05 | 0.05 | 0.345 | 0.10–1.18 | 0.09 |
| Unfavourable | 61 (29.9) | 1.057 | 0.56–1.97 | 0.86 | 0.96 | 0.45–2.01 | 0.92 |
| (b) Multivariate analysis for overall survival | |||
|---|---|---|---|
| HR | CI | p Value (log rank) | |
| Age | |||
| Adult | 4.91 | ||
| Pediatric | 1.00 | 2.64–9.12 | < 0.001 |
| Morphologic remission | |||
| No | 6.90 | ||
| Yes | 1.00 | 3.65–13.02 | < 0.001 |
| Favourable karyotype | |||
| Normal cytogenetics | 1.000 | ||
| Favourable | 0.37 | 0.12–1.09 | 0.184 |